Other · developed by Eupraxia Pharmaceuticals
EP-104IAR is given as a single intra-articular injection into the knee, in a 5 mL volume in one study and under ultrasound guidance in another. It is studied in knee osteoarthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04120402 | Phase 2 | Osteoarthritis, Knee | Completed | EPRX |
| NCT02609126 | Phase 1 | Osteoarthritis, Knee | Completed | EPRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Osteoarthritis, Knee
Updated Nov 15, 2026. Something wrong or missing? Report it on the EPRX page.
See EPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EPRX catalysts and pipeline →